Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candida albicans skin test antigen
- Development stage
- Approved
- Lead developer
- Nielsen BioSciences
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intralesional
01
Overview
Candin (Candida albicans skin test antigen) is a biological product derived from the culture filtrate and cells of *Candida albicans*, primarily indicated as a recall antigen for detecting cell-mediated hypersensitivity through intradermal testing. It is used to evaluate the cellular immune response in patients suspected of having reduced cellular hypersensitivity (anergy). Additionally, the product is being developed as an intralesional immunotherapy for the treatment of common warts (Verruca vulgaris). By injecting the antigen directly into a wart, it induces a localized delayed-type hypersensitivity (DTH) response, which recruits T-cells and other immune effectors to the site, facilitating the clearance of the underlying human papillomavirus (HPV) infection. Nielsen BioSciences is the lead developer, with Maruho partnering for commercialization in Japan and other Asian territories.
- Brand names
- Candin
- Other names
- Candida albicans skin test antigenCandida antigenCandida albicans antigen
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on candida albicans skin test antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candida albicans skin test antigen.